FDA Approves New Immunotherapy Combination for Multiple Myeloma
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Blood-Cancer.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- Broderick JM. FDA Approves Empliciti Regimen to Treat Relapsed or Refractory Myeloma. Cure Today. Available at https://www.curetoday.com/articles/fda-approves-empliciti-regimen-to-treat-relapsed-or-refractory-myeloma. Accessed 11/9/18.
- U.S. Food and Drug Administration Approves Empliciti® (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma. Business Wire. Available at https://www.businesswire.com/news/home/20181106005990/en/U.S.-Food-Drug-Administration-Approves-Empliciti%C2%AE-elotuzumab. Accessed 11/9/18.
- How does Empliciti work? Empliciti product website. Available at https://www.empliciti.com/how-it-works. Accessed 11/9/18.